Back to results
US 2006/0135486 A1Published application
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
AssigneeEisai Co., Ltd.
InventorsTakashi Owa, Yoichi Ozawa, Taro Semba
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.
Claims52
A pharmaceutical composition comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor,
- wherein the sulfonamide-including compound is at least one compound selected from the group consisting of:
- a compound of Formula (I), or a pharmacologically acceptable salt thereof or a solvate thereof:
- [wherein E represents —O—, —N(CH3)—, —CH2—, —CH2CH2— or —CH2O—, D represents —CH2— or —O—, R1a represents a hydrogen atom or a halogen atom, and R2a represents a halogen atom or a trifluoromethyl group],
- a compound of Formula (II), or a pharmacologically acceptable salt thereof or a solvate thereof:
- [wherein J represents —O— or —NH—, R1b represents a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group, an optionally substituted C1-4 alkoxy group, an optionally substituted C1-4 alkylthio group, an optionally substituted C2-5 alkoxycarbonyl group, a nitro group, an azido group, —O(SO2)CH3, —N(CH3)2, a hydroxyl group, a phenyl group, a substituted phenyl group, a pyridinyl group, a thienyl group, a furyl group, a quinolinyl group or a triazole group, R2b represents a hydrogen atom, a halogen atom, a cyano group, an optionally substituted C1-6 alkyl group, an optionally substituted C2-5 alkoxycarbonyl group, an optionally substituted C1-4 alkoxy group, an optionally substituted phenyl group or an optionally substituted quinolinyl group, R3b represents a hydrogen atom or an optionally substituted C1-4 alkoxy group, R4b represents a hydrogen atom or an optionally substituted C1-6 alkyl group (provided that at least one of R3b and R4b is a hydrogen atom), R5b represents a hydrogen atom, a halogen atom, an optionally substituted C1-6 alkyl group or a nitro group, R6b represents a hydrogen atom, a halogen atom or an optionally substituted C1-6 alkyl group (provided that when R6b is an optionally substituted C1-6 alkyl group, R5b is a hydrogen atom and R7b is a halogen atom), and R7b represents a halogen atom or an optionally substituted C1-6 alkyl group (provided that when either R5b or R7b is an optionally substituted C1-6 alkyl group or when R7b is a halogen atom or an optionally substituted C1-6 alkyl group, either R5b or R6b is a hydrogen atom)],
- a compound of Formula (III), or a pharmacologically acceptable salt thereof or a solvate thereof:
- and
- a compound of Formula (IV), or a pharmacologically acceptable salt thereof or a solvate thereof:
5 more elements
A pharmaceutical composition comprising a compound of Formula (IX):
- or a pharmacologically acceptable salt thereof or a solvate thereof in combination with an angiogenesis inhibitor.
A pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor,
- wherein the sulfonamide-including compound is a compound of Formula (XIV):
- [wherein
- the ring A represents an optionally substituted monocyclic or bicyclic aromatic ring, the ring B represents an optionally substituted 6-membered cyclic unsaturated hydrocarbon or an optionally substituted unsaturated 6-membered heterocyclic ring containing one nitrogen atom as a heteroatom,
- the ring C represents an optionally substituted 5-membered heterocyclic ring containing one or two nitrogen atoms,
- W represents a single bond or —CH═CH—,
- X represents —N(R1)— or an oxygen atom,
- Y represents:
- and
- Z represents —N(R2)—,
- wherein R1, R2 and R3, which may be the same or different, each independently represent a hydrogen atom or a lower alkyl group],
- or a pharmacologically acceptable salt thereof or a solvate thereof, and
- wherein the VEGF receptor kinase inhibitor is at least one compound selected from the group consisting of:
- (10) N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl }-N′-(5-methyl-3-isoxazolyl)urea,
- (11) 4-[(4-fluoro-2-methylindol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline,
- (12) 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole,
- (13) 5-((Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-((2S)-2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide,
- (14) 3-((quinolin-4-ylmethyl)amino)-N-(4-(trifluoromethoxy)phenyl)thiophene-2-carboxamide,
- (15) 6-(2,6-dichlorophenyl)-8-methyl-2-phenylamino-8H-pyrido[2,3-d]pyrimidin-7-one,
- (16) 2-((1,6-dihydro-6-oxo-pyridin-3-ylmethyl)amino)-N-(3-(trifluoromethyl)phenyl)-3-pyridine-carboxamide,
- (17) 4-(4-(4-chloro-phenylamino)-furo[2,3-d]pyridazin-7-yloxymethyl)-pyridine-2-carboxylic acid methylamide,
- (18) N-(3-trifluoromethyl-4-chlorophenyl)-N′-(4-(2-methylcarbamoylpyridin-4-yl)oxyphenyl)urea,
- (19) 4-amino-5-fluoro-3-(6-(4-methyl-piperazin-1-yl)-1H-benzimidazol-2-yl)-1H-quinolin-2-one,
- (20) 4-(4-(1-amino-1-methyl-ethyl)-phenyl)-2-(4-(2-morpholin-4-yl-ethyl)-phenylamino)-pyrimidine-5-carbonitrile,
- (21) [6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-((R)-1-phenylethyl)amine,
- (22) 9-(1-methylethoxy)methyl-12-(3-hydroxypropyl)-6H,7H,13H-indeno[2,1-a]pyrrolo[3,4-c]carbazol-5-one,
- (23) N-(2,4-difluorophenyl)-N′-{4-[(6,7-dimethoxy-4-quinolyl)-oxy]-2-fluorophenyl}urea,
- (24) 5-[N-methy-N-(4-octadecyloxyphenyl)acetyl]amino-2-methylthiobenzoic acid,
- (25) N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea,
- (26) 2-methyl-6-[2-(1-methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridin-7-yloxy]-benzo[b]thiophene-3-carboxylic acid methylamide,
- (27) (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol, and
- (28) (S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propan-2-ol) 2-aminopropanonate,
- or a pharmacologically acceptable salt thereof or a solvate thereof.
29 more elements
A pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor,
- wherein the sulfonamide-including compound is a compound of Formula (XIV):
- [wherein
- the ring A represents an optionally substituted monocyclic or bicyclic aromatic ring, the ring B represents an optionally substituted 6-membered cyclic unsaturated hydrocarbon or an optionally substituted unsaturated 6-membered heterocyclic ring containing one nitrogen atom as a heteroatom,
- the ring C represents an optionally substituted 5-membered heterocyclic ring containing one or two nitrogen atoms,
- W represents a single bond or —CH═CH—,
- X represents —N(R1)— or an oxygen atom,
- Y represents:
- and
- Z represents —N(R2)—,
- wherein R1, R2 and R3, which may be the same or different, each independently represent a hydrogen atom or a lower alkyl group],
- or a pharmacologically acceptable salt thereof or a solvate thereof, and
- wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropyl-aminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof or a solvate thereof.
9 more elements
48-194. (canceled)
Dependencies are inferred from the claim text.